We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.50 | 2.34% | 65.50 | 63.00 | 68.00 | 65.50 | 64.00 | 64.00 | 69,942 | 10:23:54 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.99 | 15.44M |
From May 2022 to May 2024
By Anthony O. Goriainoff
NetScientific PLC said Monday that the U.S. Food and Drug Administration has granted its PDS0101 cancer treatment a Fast Track designation in combination with Merck & Co.'s Keytruda therapy.
The London-listed life-sciences, technology, investment and commercialization company said its portfolio company PDS Biotechnology Corp. was granted the designation for the treatment of recurrent or metastatic head and neck cancer.
The company said the designation program is intended to help develop and expedite the review of drug candidate applications that can potentially treat serious or life-threatening conditions.
"The FDA fast track designation of PDS0101 provides recognition that the drug fills an unmet need in a serious condition, with the purpose to get a drug to patients faster. The board therefore considers this a significant milestone and value inflection point for PDS," Chief Executive Ilian Iliev said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 06, 2022 02:53 ET (06:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Netscientific Chart |
1 Month Netscientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
